The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model. - Clemente-Bautista S; Trocóniz IF; Segarra-Cantón Ó; Salvador-Marín S; Parramón-Teixidó CJ; Álvarez-Beltrán M; López-Fernández LA; Colom H; Cabañas-Poy MJ; Gorgas-Torner MQ; Miarons M (Paediatric drugs, 2024)